Elevated levels of parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) are hallmarks of CKD-MBD and have been implicated in the pathophysiology of adverse outcomes through mechanisms dependent and independent of alterations in mineral and bone metabolism. This evidence concerns the gene PTH and Marchiafava-Bignami disease.